Pancreatic Neoplasms
307
41
51
140
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
37 trials with published results (12%)
Research Maturity
140 completed trials (46% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.4%
29 terminated out of 307 trials
82.8%
-3.7% vs benchmark
6%
17 trials in Phase 3/4
26%
37 of 140 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 140 completed trials
Clinical Trials (307)
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Pancreatic Cancer Detection Consortium
Energy Expenditure and Nutrition After Pancreatic Surgery
A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Pancreatic Cancer Screening Using the Enzeavour Assay in Japan
Exocrine-Endocrine Pancreatic Crosstalk: Precision Pathways to Reframe Diabetes Pathophysiology
Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology
Indocyanine Green-Guided Versus Standard Laparoscopic Distal Pancreatectomy for Pancreatic Body and Tail Lesions
Digitally Supported Prehabilitation Before Major Visceral Cancer Surgery
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Clinical, Oncologic, and Metabolic Effects of Pancreatic Mass Loss After Pancreatectomy in Non-Diabetic Patients
Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer
Clinical, Oncological and Metabolic Effects of Pancreatic Mass Loss After Partial, Near-total and Total Pancreatectomy in Patients With Preoperative Diabetes Mellitus